$5.500
-0.010 (-0.18%)At close
INGN News
INGN Events
Inogen Appoints Andy Reding as Chief Operating Officer
Inogen announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen's strategy is translated into efficient and measurable outcomes. "As we continue to diversify Inogen's business through new product launches and geographic expansion, we are streamlining our leadership structure to enhance execution and accelerate delivery of our strategic priorities," said Kevin Smith, Inogen's Chief Executive Officer. "Andy's deep experience building high-performing teams and scaling complex medical technology businesses will be invaluable as we continue to drive top-line growth, advance profitability and expand the innovation pipeline."
Inogen Q1 Revenue Exceeds Estimates at $85.1M
Reports Q1 revenue $85.1M, two estimates $82.4M. "Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities that we believe will position us for growth acceleration and improved profitability in the second half of the year and beyond," said Kevin Smith, Inogen's Chief Executive Officer. "Our progress reflects the power of our strategy as we expand our addressable markets, differentiate our portfolio with clinical evidence, and broaden our portfolio through innovation as we generate long-term sustained growth, profitability and value creation for our stockholders."
Inogen Maintains FY26 Revenue Outlook of $366M-$373M
Inogen backs FY26 revenue view $366M-$373M, two estimates $368.9M
Inogen Appoints New CFO and CMO to Accelerate Growth
Inogen announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026.Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. Bourque will serve in an advisory capacity until June 30, 2026, to ensure a smooth transition. Dominic Hulton has been appointed Chief Marketing Officer, effective April 1, 2026. Mr. Hulton is a globally experienced commercial leader with over 20 years of experience driving growth, expanding markets, and leading organizational transformation in medical technology. Mr. Hulton spent the last 11 years at Insulet Corporation, where he served as Vice President of International Marketing and Sales Excellence. In that role, he led global product launches, built cross-functional teams and scaled commercial operations.
Inogen Confirms Q1 Revenue Outlook in Line with 1Q25
Inogen backs Q1 revenue view of in line with 1Q25
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.